| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | isoevodiamine | CTRPv2 | pan-cancer | AAC | -0.0051 | 0.9 |
| mRNA | Methotrexate | FIMM | pan-cancer | AAC | -0.02 | 0.9 |
| mRNA | Bryostatin 1 | FIMM | pan-cancer | AAC | -0.021 | 0.9 |
| mRNA | Topotecan | FIMM | pan-cancer | AAC | -0.016 | 0.9 |
| mRNA | UNC0321 | CTRPv2 | pan-cancer | AAC | -0.0055 | 0.9 |
| mRNA | KU-0063794 | CTRPv2 | pan-cancer | AAC | -0.0052 | 0.9 |
| mRNA | KIN001-266 | GDSC1000 | pan-cancer | AAC | -0.0049 | 0.9 |
| mRNA | tanespimycin:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.0053 | 0.9 |
| mRNA | NSC-207895 | GDSC1000 | pan-cancer | AAC | -0.0046 | 0.9 |
| mRNA | GSK-J4 | CTRPv2 | pan-cancer | AAC | 0.016 | 0.9 |